Search

Your search keyword '"Wehler, Thomas"' showing total 4 results
Start Over Author "Wehler, Thomas" Language german
4 results on '"Wehler, Thomas"'

4. [Immunotherapy in lung cancer: checkpoint inhibitors].

Author

Wehler T, Wehler B, and Stehle I

Subjects
Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antigens, Neoplasm immunology, Drug Approval, Germany, Humans, Lung Neoplasms immunology, Nivolumab, Randomized Controlled Trials as Topic, T-Lymphocytes drug effects, T-Lymphocytes immunology, Antibodies, Monoclonal therapeutic use, Immunotherapy methods, Lung Neoplasms drug therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors
Abstract

Monoclonal antibodies against the PD-1 receptor or its ligands result in a recovery of T cell responses against tumor antigens. Nivolumab is the first antibody that has been approved in lung cancer. This mode of action is very intersting, especially because of long term responses and the moderate toxicity., (© Georg Thieme Verlag KG Stuttgart · New York.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results